Previous 10 | Next 10 |
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has...
Lantheus Holdings (LNTH) , the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals (PGNX) entered into a stock purchase agreement to sell its Puerto Rico radiopharmacy and positron emission tomography ((PET)) manufacturing facility ((PMF)) to PharmaLo...
Transaction Extends Relationship with Strategic Partner Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercializati...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and p...
Lantheus (LNTH) climbs 12% in post market after the FDA approves the supplemental marketing application for Definity Room Temperature (Definity RT), a modified formulation of Definity that allows both storage and shipment at room temperature (previously approved formulatio...
Commercially Available in Early 2021 Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of i...
The FDA has granted 510(k) clearance for the use of Lantheus’ ([[LNTH]] +3.2%) artificial intelligence enabled automated bone scan index (aBSI) product on GE Healthcare’s Xeleris platform. The AI platform automates the detection of hotspots in bone indicative of metas...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and t...
The following slide deck was published by Lantheus Holdings, Inc. in conjunction with this event. For further details see: Lantheus Holdings (LNTH) Presents At Credit Suisse 29th Annual Virtual Healthcare Conference - Slideshow
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic an...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
2024-08-01 08:00:12 ET David Turkaly from JMP Securities issued a price target of $125.00 for LNTH on 2024-08-01 07:13:00. The adjusted price target was set to $125.00. At the time of the announcement, LNTH was trading at $104.83. The overall price target consensus is at...
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...